FVIII at the crossroad of coagulation, bone and immune biology: Emerging evidence of biological activities beyond hemostasis

Authors: Cade, M; Munoz-Garcia, J; Babuty, A; Fouassier, M; Heymann, M-F; Monahan, PE; Heymann, D

Affiliations: Univ Nantes, INSERM, Inst Cancerol Ouest, F-44805 St Herblain, France; CHU Nantes, Dept Haemostasis, Nantes, France ; Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA ; Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England.

Publication: Drug Discovery Today ; 2022 ; 27. 102–116

Abstract: Hemophilia A is an X-linked hereditary disorder that results from deficient coagulation factor VIII (FVIII) activity, leading to spontaneous bleeding episodes, particularly in joints and muscles. FVIII deficiency has been associated with altered bone remodeling, dysregulated macrophage polarization, and inflammatory processes that are associated with the neoformation of abnormal blood vessels. Treatment based on FVIII replacement can lead to the development of inhibitors that render FVIII concentrate infusion ineffective. In this context, hemophilia has entered a new therapeutic era with the development of new drugs, such as emicizumab, that seek to restore the hemostatic balance by bypassing pathologically acquired antibodies. We discuss the potential extrahemostatic functions of FVIII that may be crucial for defining future therapies in hemophilia.